Abstract

467 Sono-electro-magnetic therapy for treating chronic pelvic pain syndrome in men: A randomized, placebo-controlled, double-blind trial

Highlights

  • Male chronic pelvic pain syndrome (CPPS), called chronic prostatitis, is a disabling disorder characterized by a non-malignant pain in the pelvic region that lasts for at least three months without evidence of infection or other obvious pathology [1]

  • 6%–12% of men suffer from CPPS; the disease affects millions worldwide [2]

  • Between November 2009 and July 2012, 1342 men with potential CPPS were seen at our outpatient clinic and 540 were considered for inclusion into the trial

Read more

Summary

Introduction

Male chronic pelvic pain syndrome (CPPS), called chronic prostatitis, is a disabling disorder characterized by a non-malignant pain in the pelvic region that lasts for at least three months without evidence of infection or other obvious pathology [1]. 6%–12% of men suffer from CPPS; the disease affects millions worldwide [2]. It is similar to congestive heart failure, Crohn’s disease, diabetes mellitus or angina [3] in lowering quality of life, and represents a serious economic burden on any health care system. Associated costs match those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis [4]. Approximately 20% to 65% of all patients find no relief in conventional therapies [6, 8] and treatment of CPPS remains a challenge.

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.